A 72-year-old woman with Parkinson disease of 8 years' duration on levodopa 500 mg daily presents with involuntary writhing movements of her left arm and leg that appear 2–3 hours after each dose of medication and resolve before the next dose. Her motor symptoms are well-controlled during the "on" periods. She denies cognitive decline or hallucinations. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: Levodopa-Induced Dyskinesia (LID) ### Presentation Pattern **Key Point:** This patient exhibits **peak-dose dyskinesia**, a form of levodopa-induced motor complication characterized by: - Involuntary choreiform or dystonic movements - Temporal correlation with peak levodopa levels (2–3 hours post-dose) - Resolution during "off" periods - Occurs after 5–10 years of levodopa therapy (she is at 8 years) **High-Yield:** Peak-dose dyskinesia is the most common type of LID, affecting ~40% of patients on levodopa after 5 years. ### Pathophysiology Pulsatile dopamine replacement (levodopa dosing) causes: 1. Loss of nigral dopamine buffering capacity 2. Sensitization of striatal D1 receptors 3. Abnormal downstream signaling → involuntary movements ## Management Strategy for Peak-Dose Dyskinesia ```mermaid flowchart TD A[Peak-dose dyskinesia on levodopa]:::outcome --> B{Levodopa dose adequate?}:::decision B -->|Yes - symptoms controlled| C[Smooth dopamine delivery]:::action B -->|No - inadequate| D[Increase levodopa dose]:::action C --> E[Add COMT inhibitor<br/>entacapone/tolcapone]:::action C --> F[Switch to extended-release<br/>levodopa formulation]:::action D --> G[Reassess dyskinesia]:::outcome E --> H[Reduce pulsatility<br/>Improve dyskinesia]:::outcome F --> H ``` ### Rationale for Correct Answer **Entacapone or ER-Levodopa** work by: - **Entacapone:** COMT inhibitor → prolongs levodopa half-life → smoother dopamine levels → reduced pulsatility - **ER-Levodopa:** Extended-release formulation → sustained absorption → reduced peak-trough fluctuations Both strategies **reduce pulsatile dopamine stimulation**, which is the root cause of dyskinesia. | Intervention | Mechanism | Dyskinesia Reduction | Efficacy | |--------------|-----------|----------------------|-----------| | Entacapone | COMT inhibition | Moderate–good | Proven | | ER-Levodopa | Sustained release | Moderate | Proven | | Increase dose | Higher peaks | Worsens dyskinesia | ✗ Contraindicated | | Dopamine agonist | Smooth tonic stimulation | Good (adjunctive) | Proven | **Clinical Pearl:** Never increase levodopa dose in peak-dose dyskinesia — this worsens involuntary movements by increasing pulsatile dopamine peaks. Instead, optimize delivery smoothness. ## Why This Patient Is Not a Candidate for Agonist Monotherapy Switching away from levodopa entirely would: - Lose excellent motor control (her "on" periods are well-managed) - Sacrifice efficacy for dyskinesia reduction - Agonist monotherapy is inferior in established disease Instead, **maintain levodopa + optimize its delivery** with COMT inhibition or ER formulation.